ABSTRACT
Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on a nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV subtypes A and B, was assessed for efficacy against respiratory disease caused by RSV.
Adults aged ≥ 60 years, with or without underlying chronic conditions, were enrolled and randomized in a 1:1 ratio to receive a single dose of vaccine or placebo and were followed for disease caused by RSV infection during the 2022-2023 season. The 2 primary endpoints were RSV-associated lower respiratory tract disease (LRTD) with ≥ 3 and ≥ 2 symptoms; acute respiratory disease (ARD) was a key secondary endpoint. The humoral RSV-specific immune response was assessed at baseline and 14 days post-vaccination. Safety was evaluated by collection of solicited adverse events (AEs) and unsolicited AEs for 7 and 28 days post- vaccination respectively, and SAEs for the entire study period.
In total, 18348 participants were included in the final efficacy and safety analyses. Vaccine efficacy was 42.9% (95% CI: -16.1; 71.9) against RSV-associated LRTD with ≥ 3 symptoms, 59.0% (95% CI: 34.7; 74.3) against LRTD with ≥ 2 symptoms, and 48.8% (95% CI: 25.8; 64.7) against ARD. The primary objective was not met for LRTD with ≥ 3 symptoms since the lower bound of the 95% CI was below 20%, the prespecified success criterion. The vaccine-elicited immune response showed mean fold-increases of 1.7 for RSV A and B neutralizing antibodies and 2.9 and 4.3 for RSV-specific IgG and IgA, respectively. The vaccine displayed mild to moderate reactogenicity, and no safety concerns were identified.
MVA-BN-RSV induced suboptimal protection against RSV-associated LRTD, likely due to suboptimal neutralizing antibody response. The vaccine had an acceptable safety profile and confirmed immunogenicity, overall showing promise for MVA-BN-vectored constructs targeting other diseases.
Competing Interest Statement
Authors are employees at Bavarian Nordic, the sponsor of the clinical trial except Prof Welte who was the principal investigator in Germany
Clinical Trial
EudraCT 2021-004923-34, NCT05238025
Funding Statement
The study was funded by Bavarian-Nordic
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB gave ethical approval for this work, trial was approved by: IRB: WCG IRB, 1019 39th Avenue SE, Suite10 Puyllup, WA98374-2115 (IRB tracking no 20220860) IRB: Ethikkommission Medizinische Hochschule Hannover, Carl-Neuberg-Str 1, 30625 Hannover, Germany (Nr. 10289 AMG M 2022)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon request to the authors
